RARA CRAFT DATABASE for FDA Medical Devices
510(k)K162294

FDA DEVICE FACTS

BRIGHTWAY BRAND NITRILE EXAMINATION GLOVES 12”, POWDER FREE, [PURPLE] TESTED FOR USE WITH CHEMOTHERAPY DRUGS

Brightway Holdings Sdn. Bhd.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEApril 21, 2017PRODUCT CODELZA

Indications for use

BRIGHTWAY BRAND NITRILE EXAMINATION GLOVES 12", POWDER FREE, [PURPLE] TESTED FOR USE WITH CHEMOTHERAPY DRUGS is a disposable device intended for medical purpose, to be worn on the examiners hand or finger to prevent contamination between patient and examiner. The tested chemotherapy drugs and their breakthrough detection times are as follows: Test Chemotherapy Drug Name and Concentration * Arsenic Trioxide (0.1mg/ml),(100ppm) * Bleomycin Sulfate (15mg/ml),(15,000 ppm) * Busulfan(6mg/ml),(6,000 ppm) * Carmustine (BCNU) (3.3mg/ml),(3,300 ppm) * Cisplatin(1.0mg/ml), (1,000 ppm) * Cyclophosphamide/Cytoxan(20mg/ml), (20,000 ppm) * Cytarabine(100mg/ml), (100,000 ppm) * Dacarbazine(DTIC) 1Omg/ml, (10,000 ppm) * Daunorubicin(5mg/ml), (5,000 ppm) * Docetaxel(10mg/ml), (10,000 ppm) * Doxorubicin HCL(2mg/ml),(2,000 ppm) * Ellence (2mg/ml), (2,000 ppm) * Etoposide /Toposar (20mg/ml), (20,000 ppm) * Fludarabine (25mg/ml), (25,000 ppm) * Fluorouracil(50mg/ml), (50,000 ppm) * Gemcitabine/Gemzar (38mg/ml), (38,000 ppm) * Idarubicin(1.Omg/ml), (1,000 ppm) * Ifosfamide (50mg/ml), (50,000 ppm) * Irinotecan(20mg/ml), (20,000 ppm) * Mechlorethamine HCI(1.0mg/ml), (1,000 ppm) * Melphalan(5mg/ml), (5,000 ppm) * Methotrexate(25mg/ml),(25,000 ppm) * Mitomycin C(0.5 mg/ml), (500 ppm) * Mitoxantrone(2mg/ml),(2,000 ppm) * Paclitaxel(6.Omg/ml),(6,000 ppm) * Paraplatin (10mg/ml),(10,000 ppm) * Rituximab(10mg/ml),(10,000 ppm) * Thiotepa (10mg/ml),(10,000 ppm) * Trisenox(0.lmg/ml), (100 ppm) * Vincristine Sulfate(1.Omg/ml),(1,000 ppm) Minimum Breakthrough Detection Time >240 Minutes >240 Minutes >240 Minutes 127.5 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes >240 Minutes Please note that the following drug noted permeation times below 240 mins: Carmustine (BCNU) 127.50 mins.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 29, 2026